Among these studies, for XPG Asp1104His, there were 7 bladder cancer studies, 11 breast cancer studies, 7 colorectal cancer studies, 5 head and neck cancer studies, 7 lung cancer studies, 4 non-Hodgkin lymphoma studies, 3 glioma studies, 8 melanoma studies, and 14 studies with the “other cancers”. Here, ERCC5 is linked to non-Hodgkin lymphoma.